摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(嘧啶-2-氧基)苯甲醛 | 433920-92-4

中文名称
4-(嘧啶-2-氧基)苯甲醛
中文别名
4-(嘧啶-2-基氧基)苯甲醛
英文名称
4-(pyrimidinyloxy)benzenecarbaldehyde
英文别名
4-(pyrimidin-2-yloxy)benzaldehyde;4-(pyrimidin-2-yloxy)-benzaldehyde;4-(2-pyrimidinyloxy)benzaldehyde;4-pyrimidin-2-yloxybenzaldehyde
4-(嘧啶-2-氧基)苯甲醛化学式
CAS
433920-92-4
化学式
C11H8N2O2
mdl
MFCD03791174
分子量
200.197
InChiKey
CGSRJSIAGKSMHU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    76-78°C
  • 溶解度:
    >30 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    52.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xn
  • 安全说明:
    S26,S36/37
  • 危险类别码:
    R22,R36,R43
  • 海关编码:
    2933599090

SDS

SDS:139a1ecc9cc28e2b4a118898b5ce5327
查看

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Novel 2-(2-Benzylidenehydrazinyl)Benzo[d]Thiazole as Potential Antitubercular Agents
    摘要:
    采用分子杂交的方法合成了取代的2-(2-(4-芳氧苯亚甲基)肼基)苯噻唑衍生物,以2-肼基苯噻唑和4-(饱和环/芳香族/二芳烃/杂芳烃氧)苯甲醛作为新的抗结核药物。在用Resazurin微孔实验法(REMA)对H37Rv株的结核分枝杆菌进行测试时,合成化合物显示出良好的活性(最低抑菌浓度MIC为1.35-36.50μg/mL)。6-氯-2-(2-(4-(吡啶-4-氧)苯亚甲基)肼基)苯并[d]噻唑(10v)的MIC为1.35μg/mL。因此,它可以作为进一步抗结核研究的潜在候选药物。
    DOI:
    10.2174/1386207311316030009
  • 作为产物:
    描述:
    2-氯嘧啶对羟基苯甲醛2,2,6,6-四甲基-3,5-庚二酮caesium carbonatecopper(l) chloride 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 24.0h, 以52%的产率得到4-(嘧啶-2-氧基)苯甲醛
    参考文献:
    名称:
    2-苯氧基嘧啶通过钯催化的CH键活化的邻位官能化
    摘要:
    已经描述了2-芳氧基嘧啶的钯催化的直接乙酰氧基化和芳基化。芳香族CH键可以中度至优异的产率官能化,为合成具有抗分枝杆菌和除草活性的酚衍生物提供了一种简便的方法。
    DOI:
    10.1021/jo901316b
点击查看最新优质反应信息

文献信息

  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季铵盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
  • Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
    申请人:CoCensys, Inc.
    公开号:US20020061886A1
    公开(公告)日:2002-05-23
    This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R 1 , R 21 , R 22 and R 23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R 22 and R 23 , together with the N, form a heterocycle; A 1 and A 2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR 24 , CR 25 R 26 , C(O), NR 24 C(O), C(O)NR 24 , SO, SO 2 or a covalent bond; where R 24 , R 25 and R 26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.
    这项发明涉及由式I表示的含有碳环和杂环取代的半卡巴松和硫代半卡巴松: 1 或其药学上可接受的盐或前药,其中: Y为氧或硫;R 1 ,R 21 ,R 22 和R 23 独立地为氢,烷基,环烷基,烯基,炔基,卤代烷基,芳基,氨基烷基,羟基烷基,烷氧基烷基或羧基烷基;或R 22 和R 23 ,与N一起形成一个杂环;A 1 和A 2 独立地为芳基,杂芳基,饱和或部分不饱和的碳环或饱和或部分不饱和的杂环,其中任何一个可选择地被取代;X为O、S、NR 24 、CR 25 R 26 、C(O)、NR 24 C(O)、C(O)NR 24 、SO、SO 2 或共价键;其中R 24 ,R 25 和R 26 独立地为氢,烷基,环烷基,烯基,炔基,卤代烷基,芳基,氨基烷基,羟基烷基,烷氧基烷基或羧基烷基。该发明还涉及利用含有碳环和杂环取代的半卡巴松和硫代半卡巴松治疗全脑和局部缺血后的神经损伤,治疗或预防神经退行性疾病如肌萎缩侧索硬化症(ALS),治疗和预防耳神经毒性和涉及谷氨酸毒性的眼病,以及治疗、预防或改善疼痛,作为抗癫痫药,作为抗躁狂抑郁药,作为局部麻醉药,作为抗心律失常药,以及治疗或预防糖尿病性神经病变和尿失禁。
  • COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
    申请人:Wong Norman C.W.
    公开号:US20080188467A1
    公开(公告)日:2008-08-07
    The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
    本公开涉及化合物,这些化合物可用于调节载脂蛋白A-I(ApoA-I)的表达,以及它们用于治疗和预防心血管疾病及相关疾病状态,包括胆固醇或脂质相关紊乱,例如,动脉粥样硬化。
  • 6-O-acyl ketolide antibacterials
    申请人:——
    公开号:US20030220272A1
    公开(公告)日:2003-11-27
    6-O-Acyl ketolide antibacterials of the formula: 1 wherein R 1 , R 2 , R 3 , R 4 , W, X, X′, Y, and Y′ are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    其中R1、R2、R3、R4、W、X、X'、Y和Y'如本文所述,并且其中取代基具有描述中指示的含义。这些化合物可用作抗菌剂。
  • 6-O-carbamoyl ketolide antibacterials
    申请人:Ortho-McNeil Pharmaceutical, Inc.
    公开号:US06613747B2
    公开(公告)日:2003-09-02
    6-O-Carbamoyl ketolide antibacterials of the formula: wherein R1, R2, R3, R4, R5, R6, X, X′, Y, and Y′ are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.
    其中R1、R2、R3、R4、R5、R6、X、X'、Y和Y'如本文所述,并且其中取代基具有描述中指示的含义。这些化合物可用作抗菌剂。
查看更多